The diagnosis and subclassification of Sertoli cell tumors (SCT) of the testis are often challenging to general surgical pathologists due to the rarity of the tumors.
Introduction
Sertoli cell tumors (SCT) of the testis are most common in middle age and represent approximately 1% of all testicular tumors 1 . Most SCTs are of the "not otherwise specified (NOS)" type, but there are separate variants including the large cell calcifying Sertoli cell tumor (LCCSCT), intratubular large cell hyalinizing Sertoli cell neoplasia, and the sclerosing Sertoli cell tumor (SSCT). [1] [2] [3] [4] [5] The former two variants are associated with two important clinical conditions, the Carney complex and Peutz-Jeghers syndrome, respectively, which makes their distinction from SCT-NOS and other sex cord-stromal tumors critical. The differentiation of SCT from other sex cord-stromal tumors and the determination of SCT variants are mainly based on histological examination, which can be challenging to general surgical pathologists due to the rarity of these neoplasms. Immunohistochemistry (IHC) staining for various markers, including inhibin, calretinin, and steroidogenic factor-1, have shown limited diagnostic value in differentiating among SCTs and other tumors in the sex cord-stromal group. 6, 7 β-catenin is a component of adherens junctions on the cell membranes. 8 Under certain neoplastic conditions, this protein accumulates in the nucleus, and nuclear localization of β-catenin has been reported as a useful diagnostic marker for some tumors such as desmoid tumor, hepatoblastoma, and pancreatic solid pseudopapillary tumor. [9] [10] [11] Consistent β-catenin nuclear staining has also been reported in ovarian microcystic stromal tumors. 12, 13 The expression of β-catenin in nonneoplastic Sertoli cells is limited to the cytoplasm and membranes. 14 Recently, Perrone et al reported 14 cases of SCT in which β-catenin nuclear localization was demonstrated in a high proportion of cases (10/14) . 15 One case of SSCT with β-catenin nuclear localization was later reported by the same group 16 Furthermore, this reactivity correlated highly with mutation in the CTNNB1 gene, which encodes for β-catenin and leads to its accumulation. 15, 16 A case of bilateral SCTs in a patient with familial adenomatous polyposis, a condition associated with germline mutation in the APC gene (whose non-mutated protein normally participates in β-catenin degradation), showed strong nuclear β-catenin immunostaining. 17 These findings suggest that β-catenin nuclear localization may play an important role in the formation of some SCTs and also may be used as a potential marker for the diagnosis of SCTs. However, the exact frequency of β-catenin nuclear localization in SCTs of testis is unknown because of the limited number of cases reported to date; and it is furthermore unknown whether nuclear β-catenin staining is specific for SCTs among testicular sex cord-stromal tumors. In this study, we evaluated the status of β-catenin nuclear localization in a relatively large cohort of SCTs, as well as in various other testicular sex cord-stromal tumors.
Materials and Methods
Case selection: A total of 87 resected sex cord-stromal tumors (including 33 SCTs-NOS Results of our study show frequent (over 60%) positive nuclear staining for β-catenin in SCT-NOS and SSCT, which is in agreement with a previous report by Perrone et al. 15 Additionally, our results suggest that β-catenin nuclear staining is completely specific for SCTs among all sex cord-stromal tumors. Although a negative nuclear reaction for β-catenin cannot exclude a diagnosis of SCT, positive nuclear staining, in our hands, is specific for SCT-NOS, change that may be confused with tubule formation. 18 Cytokeratin and α-inhibin immunohistochemical stains have been reported helpful but are not definite in differentiating the two tumors. 7 In our study, all 10 Leydig cell tumors were consistently negative for nuclear β-catenin. Therefore, positive nuclear β-catenin stain supports the diagnosis of SCT and argues strongly against the diagnosis of Leydig cell tumor.
Unclassified sex cord-stromal tumor is a heterogeneous group of sex cord-stromal tumors that cannot be adequately classified into a specific group based on morphologic characteristics. Our results showed consistent negative nuclear reaction of β-catenin in this heterogeneous group of tumors, helping to distinguish them from SCTs.
Nuclear positivity for β-catenin is also of assistance in the subtyping of SCTs. All
LCCSCTs were negative, making a positive reaction useful in its exclusion from a differential diagnosis. This is a clinically important distinction because of the linkage of the LCCSCT to the Carney complex and is entirely consistent with the pathogenesis of LCCSCT being separate from that of SCT-NOS and SSCT, a concept additionally supported by its association with PRKAR1A gene mutation. 3, 19 Besides its potential diagnostic value for SCTs, our finding also supports the previous experimental and clinical evidences linking β-catenin nuclear accumulation with the pathogenesis of SCTs of the testis. β-catenin is a cell membrane protein that links cadherin adhesion receptors to α-catenin, which in turn links to the cytoskeleton. 8, 20, 21 Cytoplasmic β-catenin interacts with the adenomatous polyposis coli (APC) and axin proteins, which recruit glycogen synthase kinase-3 and casein kinase I to form a destruction complex that rapidly phosphorylates and degrades β-catenin. 22, 23 Little cytoplasmic residue of β-catenin is present under normal condition. During some neoplastic processes, the destruction complex is inhibited and, as a result, the level of free cytoplasmic β-catenin rises and β-catenin enters the nucleus and binds with the T-cell factor/lymphoid-enhancing factor family. This transcriptional complex interacts with the promoters of various target genes affecting cell growth. 24, 25 Laboratory studies have revealed roles of β-catenin in the pathogenesis of SCTs. Conditional stabilization of β-catenin in Sertoli cells caused inhibition of Mullerian duct regression in mice, and overactive β-catenin signaling due to a mutated CTNNB1 gene was found to cause testicular Sertoli cell tumor development in a mouse model. 26, 27 The pathogenic role of β-catenin in SCTs is supported by results of our study as well as those of Perrone et al, which showed that all SCTs with β-catenin nuclear staining (10/10) had mutations in exon 3 of the CTNNB1 gene. 15 One aspect of our study was the high incidence of β-catenin nuclear localization in SSCTs, a finding suggesting a similar pathogenic mechanisms for its formation. Although the SSCT has less frequently displayed malignant behavior compared to SCT-NOS, it may, on occasion, prove malignant. 4, 5 Its relatively favorable prognosis may, therefore, simply be a consequence of its usually smaller size and decreased cellularity compared to SCT-NOS rather 10 than reflecting a distinctive clinicopathologic entity. The results of this study support that viewpoint.
In summary, results of our study showed that SCT-NOS, SSCT, and Sertoli-stromal cell tumor frequently demonstrate β-catenin nuclear localization, which is not seen in any other type of sex cord-stromal tumor of the testis. β-catenin is, therefore, a useful marker for the diagnosis of SCT and the determination of subtypes of SCTs. and Sertoli-stromal cell tumor (E and F).
